Clinical Trial Update: Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis [Phase 4]

View source ↗

Summary

A Phase 4 study is evaluating Telitacicept plus low-dose corticosteroids for refractory Myasthenia Gravis; the trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Corticosteroids (low-dose) (corticosteroids)
• Telitacicept

Snippet

Sponsor: First Affiliated Hospital of Wenzhou Medical University | Conditions: Myasthenia Gravis, Autoimmune Diseases | Phase 4 | Status: NOT_YET_RECRUITING